The Centers for Medicare and Medicaid (CMS) Release Billing Guidelines for COVID-19 Vaccine
WellCare of New Jersey is closely following advancements in the prevention and treatment of COVID-19, including vaccinations. As a healthcare provider, you will play an integral role as COVID-19 vaccines become available. We want to update you on important new information about vaccine coverage.
To prepare for vaccine administration, the Centers for Medicare and Medicaid (CMS) have published billing guidance (PDF) for Medicaid and Children’s Health Insurance Program (CHIP) providers. Similar to other COVID-19 services, the vaccines will be offered at no cost to your patients. In addition:
- WellCare of New Jersey will configure its systems to properly adjudicate COVID-19 vaccine-related claims, both for the vaccine and its administration, in accordance with New Jersey’s coverage determinations for Medicaid beneficiaries
- La responsabilidad de los miembros será de $0
- Non-participating provider pre-auth requirements will be waived
- Las tasas de reembolso a los proveedores y las autorizaciones de uso de emergencia (EUA) continúan pendientes, por lo que le informaremos a medida que dicha información esté disponible
The American Medical Association (AMA) has published updates to the Current Procedural Terminology (CPT®) code set that includes new vaccine-specific codes to report immunizations for the novel coronavirus (SARS-CoV-2). The code set will continue to be updated as additional vaccines receive EUA approval by the U.S. Food & Drug Administration (FDA).
The following codes have been published as of November 10, 2020. However, they will not be billable until the specific vaccine receives official EUA approval.
|
Código |
Descriptor breve de CPT |
Nombre del etiquetado |
Nombre de la vacuna/del procedimiento |
|
91300 |
SARSCOV2 VAC 30MCG/0.3ML IM |
Pfizer |
Vacuna contra el COVID-19 de Pfizer-Biotech |
|
0001A |
ADM SARSCOV2 VAC 30MCG/0.3ML 1ST |
Pfizer |
Vacuna contra el COVID-19 de Pfizer-Biotech Administración – Primera dosis |
|
0002A |
ADM SARSCOV2 VAC 30MCG/0.3ML 2ND |
Pfizer |
Vacuna contra el COVID-19 de Pfizer-Biotech Administración – Segunda dosis |
|
91301 |
SARSCOV2 VAC 100MCG/0.5ML IM |
Moderna |
Vacuna contra la COVID-19 de Moderna |
|
0011A |
ADM SARSCOV2 VAC 100MCG/0.5ML 1ST |
Moderna |
Vacuna contra la COVID-19 de Moderna Administración – Primera dosis |
|
0012A |
ADM SARSCOV2 VAC 100MCG/0.5ML 2ND |
Moderna |
Vacuna contra la COVID-19 de Moderna Administración – Segunda dosis |
Additionally, CMS has also published a set of toolkits to help providers prepare to swiftly administer the vaccine once it is available. If you have any further questions about this upcoming vaccine or the COVID-19 services WellCare of New Jersey covers, please contact Provider Services at 1-888-453-2534.